Acadia Pharma GAAP EPS of $0.42 beats by $0.28, revenue of $278.6M beats by $2.06M
Source: SeekingAlpha
2025-11-05 16:13:47 ET
More on Acadia Pharma
- ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish
- Acadia Pharmaceuticals: Reeling After PWS Failure - Downgrading To Hold
- ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
- Acadia Pharma Q3 2025 Earnings Preview
- Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps
Read the full article on Seeking Alpha
For further details see:
Acadia Pharma GAAP EPS of $0.42 beats by $0.28, revenue of $278.6M beats by $2.06M
ACADIA Pharmaceuticals Inc.
NASDAQ: ACAD
ACAD Trading
-1.34% G/L:
$21.025 Last:
573,736 Volume:
$21.41 Open:
ACAD Latest News
March 12, 2026 04:05:00 pm
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
March 09, 2026 09:54:00 am
Neuropsychiatric Innovation Draws Big Pharma Interest and Fresh Investment
March 03, 2026 04:05:00 pm
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
ACAD Stock Data
$3,864,112,700
124,348,635
0.05%
128
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
